IJCRR - Vol 08 Issue 01, January, 2016
COMPARISION OF THE ADVERSE EFFECTS PROFILE OF TRAVOPROST VS BRIMONIDINE/TIMOLOL IN PATIENTS OF PRIMARY OPEN ANGLE GLAUCOMA IN CENTRAL IDIAN POPULATION OF BHOPAL
Author: Rekha Mehani, Major V. K. Yadav, Rajnish Kumar Sankadia, Sarang Ghodki, Tanu Garg
Aim: To compare the adverse effects profile of Travoprost vs Brimonidine/Timolol in patients of Primary Open Angle Glaucoma(POAG) Methodology: In this randomized open label 12-week study, 70 patients were randomized to receive either 0.004% of Travoprost once daily in the evening or Brimonidine/Timolol combination twice daily. Their safety was concluded by monitoring their adverse effects during follow-up visits at 2, 4, 8, and 12 weeks. Results: Both treatment regimens were well tolerated during the period of study. Patients in the Travoprost group had a higher incidence of ocular irritation (30%), pigmentation of skin (33%), Thickening of eyelashes (39%) and hyperemia (36%) when compared to the Brimonidine/Timolol group which showed only ocular irritation (21%) and foreign body sensations (28%). Conclusions: The incidence of adverse effects were not significantly different between Travoprost and Brimonidine/Timolol therapy. Both had favourable safety profiles. However, Travoprost had more local side effects profile when compared to Brimonidine/Timolol.
Keywords: Beta blocker, Intraocular pressure, Prostaglandin analogue, ?2 agonist, Adverse effects
Rekha Mehani, Major V. K. Yadav, Rajnish Kumar Sankadia, Sarang Ghodki, Tanu Garg. COMPARISION OF THE ADVERSE EFFECTS PROFILE OF TRAVOPROST VS BRIMONIDINE/TIMOLOL IN PATIENTS OF PRIMARY OPEN ANGLE GLAUCOMA IN CENTRAL IDIAN POPULATION OF BHOPAL International Journal of Current Research and Review. Vol 08 Issue 01, January, 51-54
1. Cantor LB, Hoop J, Morgan L, et al. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and Travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90(11):1370–1373.
2. Congdon N, O Colmain B, Klaver CC, et al. causes and prevalence of visual impairment among adults in united states. Arch Ophthalmol, 2004, 122:477-85
3. DuBiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of Travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. ClinTher 2004; 26:35-47.
4. Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2007;1(1)11–24.
5. Franks WA, Renard JP, Cunliffe IA, et al. A 6-week, doublemasked, parallel-group study of the efficacy and safety of Travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28(3):332–339.
6. Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical Travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10(5):414–422.
7. Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of IOP and glaucoma progression results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279.
8. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of Travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17(5):421–43
9. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13. [PubMed]
10. Laurence L. Bruton editor. Goodman and Gilman`s The Pharmacological Basis of Therapeutics, 12th edition, ocular pharmacology, New York Mc Graw Hill 2011.
11. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48–56. [PubMed]
12. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–53. [PubMed]
13. Morrison JC. 2005. Elevated intraocular pressure and optic nerve injury models in the rat. J Glaucoma, 14:315-7.
14. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472– 484.
15. SchachtschabelU, LindseyJD, WeinrebRN. Themechanismofaction of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11(2):112–115.
16. Schuman JS. 2000. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology, 107:1171-7. Quigley HA. 1996. Number of people with glaucoma worldwide.Br J Ophthalmol, 80:389-93.
17. Sharif NA, Crider JY, Husain S, et al. Human ciliary muscle cell responses to FP-class prostaglandin analogs: Phosphoinositide hydro- lysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther. 2003;19(5):437–455.
18. Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19(6):501–515.
19. The AGIS Investigators. The advanced glaucoma intervention study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429–440.
20. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–7. [PubMed].
21. Quigley HA. 1996. Number of people with glaucoma worldwide.Br J Ophthalmol, 80:389-93.